Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Licenses Global Rights to Kyoto iPS Cell Patents

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has licensed worldwide rights to Kyoto University's induced pluripotent stem cell patent portfolio.

Under terms of the deal, iPS Academia Japan, which managed the patents and technology arising from Shinya Yamanaka's research at Kyoto University, will receive a license fee from Sigma-Aldrich. Financial and other terms of the license were not disclosed.

"Our license with Kyoto University grants us the freedom to operate under Kyoto University's induced pluripotent stem cell patent portfolio in the increasingly important field of stem-cell based research and development," David Smoller, chief scientific officer of Sigma-Aldrich, said in a statement. "Using the Kyoto iPS cell technology and our zinc finger protein technologies, we hope to generate stable, defined sets of cells and subsequently derived tissues whose predictive power will allow us to develop a new paradigm in assay development."

Cellular Dynamics also holds a non-exclusive license to the Kyoto iPS cell patents.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.